A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

Phase 2

Completed

• Conditions: Pediatric; Hodgkin's Disease
• Interventions: Drug: COPP/ABV; Drug: intensive chemo with concurrent growth factor

• Registration Number: NCT00592111
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 1996-03
• Primary Completion: 1999-02
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study Completion: 2008-01
• Study First Posted: 2008-01-11
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-21
• Last Update Posted: 2015-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	COPP/ABV	-
2	COPP/ABV	-
3	intensive chemo with concurrent growth factor	-

Primary Outcome Measures

Name	Time	Method
Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy	Conclusion of the study

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States